What is the 13F Pro Quality Score for CELC?

13F Pro ranks Celcuity Inc. (CELC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CELC's current score at https://13fpro.ai/research/CELC (free sign-up required for the full ranking).

Which hedge funds own the most CELC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CELC include BAKER BROS. ADVISORS, Avoro Capital Advisors, PERCEPTIVE ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CELC as soon as new 13F filings post.

Where does 13F Pro source CELC data?

All Celcuity Inc. fundamentals and ownership data come directly from SEC EDGAR. Celcuity Inc. files with the SEC under CIK 1603454. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CELC in?

Celcuity Inc. (CELC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CELC research updated on 13F Pro?

CELC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Celcuity Inc.(CELC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1603454 CELC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CELC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Celcuity Inc. (CELC), a Healthcare sector company. CELC is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Celcuity Inc. reports net income of $-52.8M, free cash flow of $-55.3M. Top institutional holders of CELC by reported 13-F value include BAKER BROS. ADVISORS, Avoro Capital Advisors, PERCEPTIVE ADVISORS, based on the most recent SEC filings. CELC trades on the Nasdaq exchange and files with the SEC under CIK 1603454. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celcuity Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-52.8M

Free Cash Flow

Q1 2026

$-55.3M

D/E Ratio

Q1 2026

2.58

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-58.4% YoY

$-177.0MFY 2025

FY22 $-40.4MFY23 $-63.8MFY24 $-111.8MFY25 $-177.0M

Operating Income

-52.0% YoY

$-172.2MFY 2025

FY22 $-39.4MFY23 $-66.2MFY24 $-113.3MFY25 $-172.2M

EPS (Diluted)

-33.9% YoY

$-3.79FY 2025

FY22 $-2.64FY23 $-2.69FY24 $-2.83FY25 $-3.79

Total Assets

+90.3% YoY

$466.6MFY 2025

FY22 $175.7MFY23 $191.2MFY24 $245.1MFY25 $466.6M

Total Debt

+30.9% YoY

$137.5MFY 2025

FY22 $35.8MFY23 $37.6MFY24 $105.1MFY25 $137.5M

Op. Cash Flow

-83.6% YoY

$-153.3MFY 2025

FY22 $-36.0MFY23 $-53.8MFY24 $-83.5MFY25 $-153.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-177.0M -58.4%	$-111.8M -75.3%	$-63.8M -58.0%	$-40.4M -36.4%	$-29.6M -212.5%	$-9.5M
Operating Income	$-172.2M -52.0%	$-113.3M -71.0%	$-66.2M -68.1%	$-39.4M -38.9%	$-28.4M -196.7%	$-9.6M
EPS (Diluted)	$-3.79 -33.9%	$-2.83 -5.2%	$-2.69 -1.9%	$-2.64	—	—
Total Assets	$466.6M +90.3%	$245.1M +28.2%	$191.2M +8.8%	$175.7M +104.5%	$85.9M +563.0%	$13.0M
Total Debt	$137.5M +30.9%	$105.1M +179.8%	$37.6M +5.1%	$35.8M +123.8%	$16.0M	—
Operating Cash Flow	$-153.3M -83.6%	$-83.5M -55.1%	$-53.8M -49.4%	$-36.0M -77.3%	$-20.3M -184.3%	$-7.1M

AI Insight: CELC Financial Trends

Celcuity's cash burn accelerated sharply in Q1 2026 while equity eroded to $54M, signaling critical runway concerns.

• Operating losses widened from $24M in Q2 2024 to $51M in Q1 2026, a 112% increase over 22 months.

• Operating cash outflow hit $55M in Q1 2026, worst quarterly burn on record despite flat total debt at $138M.

• Shareholder equity collapsed 69% from $177M in Q2 2024 to $54M in Q1 2026, approaching insolvency risk.

⚠ Cash runway likely <12 months at current $55M quarterly burn; equity cushion now minimal at $54M.

⚠ Total debt rose $33M (31%) from Q2 2024 to Q1 2026 while equity fell; leverage ratio deteriorating dangerously.

AI Insight: CELC Ratio Trends

Celcuity remains deeply unprofitable with worsening leverage and negative returns across all metrics through Q1 2026.

• ROA deteriorated from -32.4% in Q2 2024 to -51.5% in Q1 2026, signaling persistent asset inefficiency.

• Debt-to-equity spiked to 2.58 in TTM (Mar 2026), up from 0.59 in Q2 2024, nearly quadrupling leverage.

• ROIC remained severely negative throughout the period, ranging -34.5% to -97.5%, with no stabilization trend.

⚠ D/E volatility (0.59–2.58) suggests capital structure instability; monitor debt refinancing and covenant compliance.

⚠ No operating or net profit margins reported; inability to disclose suggests potential losses mask underlying business viability.

Get alerted when CELC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Celcuity Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CELC

BAKER BROS. ADVISORS LP
$903.5M7,915,792 sh
Avoro Capital Advisors LLC
$385.2M3,375,000 sh
PERCEPTIVE ADVISORS LLC
$356.9M3,127,200 sh
RTW INVESTMENTS, LP
$346.9M3,039,621 sh
BlackRock, Inc.
$309.5M2,711,532 sh
NEA Management Company, LLC
$260.9M2,285,561 sh
LINDEN ADVISORS LP
$226.4M92,715,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$203.5M1,782,894 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$195.6M1,714,000 sh
STATE STREET CORP
$173.3M1,518,705 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$903.5M	7,915,792
Avoro Capital Advisors LLC	$385.2M	3,375,000
PERCEPTIVE ADVISORS LLC	$356.9M	3,127,200
RTW INVESTMENTS, LP	$346.9M	3,039,621
BlackRock, Inc.	$309.5M	2,711,532
NEA Management Company, LLC	$260.9M	2,285,561
LINDEN ADVISORS LP	$226.4M	92,715,000
VANGUARD CAPITAL MANAGEMENT LLC	$203.5M	1,782,894
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$195.6M	1,714,000
STATE STREET CORP	$173.3M	1,518,705

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CELC on your watchlist

Track score changes the day Celcuity Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CELC a good stock to buy?

13F Pro's AI-powered analysis of Celcuity Inc. (CELC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CELC are available on the CELC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CELC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CELC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Celcuity Inc.'s investment landscape.